New Findings Reported from National and Kapodistrian University of Athens Describe Advances in Waldenstrom Macroglobulinemia (Proteasome Inhibitor-based Regimens In the Frontline Management of Waldenstr & Ouml;m Macroglobulinemia).

In an individualized therapy approach, PIs can be a part of chemotherapy-containing or chemotherapy-free, fixed-duration regimens for patients not eligible for chemotherapy or at high risk for IgM-related complications." Keywords: Athens; Greece; Europe; Antineoplastics; Bortezomib Therapy; Chemotherapy; Drugs and Therapies; Health and Medicine; Macroglobulins; Oncology; Pharmaceuticals; Proteins; Serum Globulins; Waldenstrom Macroglobulinemia EN Athens Greece Europe Antineoplastics Bortezomib Therapy Chemotherapy Drugs and Therapies Health and Medicine Macroglobulins Oncology Pharmaceuticals Proteins Serum Globulins Waldenstrom Macroglobulinemia 462 462 1 09/25/23 20230925 NES 230925 2023 SEP 25 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Data detailed on Oncology - Waldenstrom Macroglobulinemia have been presented. According to the news reporters, the research concluded: "Although the treatment approach for WM is changing, PIs remain a treatment option for select patients with WM. [Extracted from the article]

Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)